Search results
14 cze 2024 · Graves' disease is an autoimmune disorder that causes hyperthyroidism and affects many organs in the body. Learn about the common symptoms, such as enlarged thyroid, bulging eyes and nervousness, and how it's diagnosed and treated.
Choroba Gravesa-Basedowa, choroba Basedowa (łac. struma diffusa toxica) – schorzenie autoimmunologiczne o cechach nadczynności tarczycy, w którym autoantygenem jest receptor TSH (TSHR) – jego pobudzenie przez przeciwciała anty-TSHR powoduje wzmożone wydzielanie hormonów tarczycy i objawy nadczynności tarczycy, a także stymuluje wzrost tarczycy i...
Graves' disease is an autoimmune disorder that affects the thyroid and causes hyperthyroidism, goiter, and sometimes eye problems. Learn about the possible genetic and environmental factors, the diagnostic methods, and the treatment options such as radioiodine, medications, and surgery.
30 mar 2022 · Choroba Gravesa i Basedowa (ChGB) jest chorobą autoimmunologiczną tarczycy, w której organizm produkuje przeciwciała przeciwko receptorowi TSH (TSHR), który znajduje się w komórkach tarczycy. Przeciwciała (TRAb) pobudzają czynność wydzielniczą tarczycy, co prowadzi do objawów nadczynności tarczycy.
6 lip 2022 · Graves’ disease is an autoimmune disorder that causes hyperthyroidism, a condition in which your thyroid gland produces too much hormone. Learn about the symptoms, diagnosis, treatment and prevention of this condition that affects your metabolism, heart, eyes and more.
Graves’ disease is an autoimmune disorder that causes hyperthyroidism, or overactive thyroid. Learn about the symptoms, complications, diagnosis, and treatment options for this condition from the National Institute of Diabetes and Digestive and Kidney Diseases.
20 cze 2023 · Graves' disease is an autoimmune disease which primarily affects the thyroid gland. It may also affect multiple other organs including eyes and skin. It is the most common cause of hyperthyroidism.[1] In this chapter, we attempt to review different aspects of Graves’ disease.
